Foundry120 atlas

Redefining the practical utility of blood transcriptome biomarkers in inflammatory bowel diseases

Download from source ↗

Dataset overview

Participants None
Samples 336
Reuse readiness 3.9/10 evidence-backed score

Whole blood RNA sequencing identifies transcriptional differences between primary sclerosing cholangitis and ulcerative colitis.

Abstract

<h4>Background & aims</h4>Genetic and microbiome studies across patients with primary sclerosing cholangitis (PSC) and ulcerative colitis (UC) have indicated that UC in PSC is a separate disease entity to primary UC, but expression studies for PSC are lacking.<h4>Methods</h4>We conducted whole blood RNA sequencing experiments for 495 patients with UC, 220 patients with PSC (including 177 with UC), and 320 healthy controls from Germany and Norway. Differential expression analyses, gene ontology and coexpression analyses and random forest machine learning were performed to identify genes, ontologies and transcriptional features that discriminate diagnoses.<h4>Results</h4>The blood transcriptome in UC and PSC is dominated by neutrophil activation genes (<i>e.g. S100A12</i>). In UC, but not in PSC (neither PSC alone nor patients with an additional diagnosis of UC [PSC/UC]), ribosomal, mitochondrial, and energy metabolism genes are upregulated in conjunction with antibody transcript expression (<i>MZB1</i>, <i>IGJ</i>). In PSC, there is an increase in modules related to apoptosis and expression of genes of interferon-I-related ontologies. Random forest analysis could poorly discriminate PSC alone from PSC/UC (AUROC 0.56), but could discriminate PSC, UC, and controls with high accuracy (AUROC UC <i>vs.</i> controls 0.95, PSC <i>vs.</i> controls 0.88, UC <i>vs.</i> PSC 0.986). The main coexpression modules relevant for distinguishing PSC, UC, and controls are enriched in neutrophil degranulation and antibody production genes.<h4>Conclusions</h4>Supported by machine learning results, PSC and UC appear to be separate entities on a molecular level, while PSC/UC and PSC are indistinguishable.<h4>Impact and implications</h4>Clinical and genetic studies suggest that the colitis-like symptoms in primary sclerosing cholangitis (PSC) represent a different disease entity from primary ulcerative colitis (UC). The present study supports this assumption with transcriptomic data from whole blood and describes notable differences in gene expression between primary UC and PSC, providing insights into the still unclear pathophysiology of both diseases. These findings are of interest to scientists seeking to decipher the molecular pathophysiology of both diseases and provide evidence that a redefinition of the PSC-UC phenotype should be considered. The study practically supports future molecular research by providing a large transcriptomic whole blood reference cohort.

Study facts

Organism
Platform
Ion Torrent Proton
Age group
mixed
Disease groups
Anatomical sites

Data availability

Specific data assets have not been resolved from the source yet — see the source repository below for the full file listing.

Strengths & limitations for reuse

Strengths

  • Raw reads are advertised
  • Sample counts are documented

Limitations

  • Not documented: feature/otu tables are advertised
  • Not documented: taxonomic tables are advertised
  • Not documented: participant counts are documented
Extraction evidence & provenance

Each extracted field is shown with the source excerpt and location used to resolve it.

Assay

FieldValueEvidence
assay.platform Ion Torrent Proton from source
ENA instrument_model=Ion Torrent Proton

Section ENA study report, offset —

Cohort

FieldValueEvidence
cohort.age_group mixed
Of these, 51 and 46 samples were from paediatric and adult patients with CD, 51 and 49 samples were from paediatric and adult patients with UC, and 50 and 46 samples were from control children and adults, respectively.

Section 3.1. The discovery step, offset 11300

cohort.disease_activity_metadata_available True
In total, 31 patients in each paediatric IBD subgroup and seven patients in each adult IBD subgroup had active disease [with a score above 30] at blood collection.

Section 3.1. The discovery step, offset 11480

cohort.study_design cross_sectional inferred
In total, 31 patients in each paediatric IBD subgroup and seven patients in each adult IBD subgroup had active disease [with a score above 30] at blood collection.

Section 3.1. The discovery step, offset 11480

cohort.treatment_exposure_documented True
Before inclusion most patients were given mesalazine, but for majority of them the blood samples were collected before additional medications [immunosupressants, glucocorticoids, biological therapy] were ordered.

Section 2.2. Subjects, offset 6900

Data_Assets

FieldValueEvidence
data_assets.pipeline_or_tool_versions True
Signal processing and base calling were conducted with Torrent Suite version 5.0.4. Reads were mapped to the hg19 AmpliSeq Transcriptome version 1 genome.

Section 2.4. RNA sequencing, reads processing, and statistical analysis, offset 9500

data_assets.raw_reads True
The RNA sequencing datasets generated during the study were deposited in European Nucleotide Archive under the PRJEB28822 accession number.

Section 2.6. Data accessibility statement, offset 10500

Specimens

FieldValueEvidence
specimens.body_site whole peripheral blood
we used the Ion AmpliSeq Transcriptome Human Gene Expression Kit to sequence 293 RNA samples extracted from whole peripheral blood.

Section 3.1. The discovery step, offset 11170

specimens.number_of_samples 336 from source
ENA sample_count=336

Section ENA study report, offset —